Traws Pharma (TRAW), a clinical-stage biotech firm focused on respiratory viral diseases, has reported significant progress in the development of its investigational treatment for H5N1 bird flu, tivoxavir marboxil. This breakthrough comes at a time when avian flu is increasingly recognized as a potential global health threat. Dr. Robert R. Redfield, Chief Medical Officer at […]